Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of fosamprenavir/ritonavir (Telzir) in HIV/HCV co-infected patients
2008-001749-25Phase 4Terminated
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fosamprenavir in human immunodeficiency virus infection (HIV) and hepatitis C virus infection, sponsored by Mater Misericordiae University Hospital. Primary endpoint: Incidence of grade 3-4 ALT or AST elevations at 48 weeks. Started Apr 2008; status: terminated.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis C virus infection
Beyond the preview
Go deeper on 2008-001749-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001749-25.